X4 Pharmaceuticals (XFOR) Preferred Stock Liabilities (2017 - 2021)

X4 Pharmaceuticals (XFOR) has reported Preferred Stock Liabilities for 3 consecutive years, with $1.9 million the latest figure, recorded in Q2 2021.

• For the quarter ending Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Jun 2021 stood at $1.9 million (changed N/A YoY), and the FY2018 full-year result was $64.7 million, up 6.19% from the prior year.
• Preferred Stock Liabilities held at $1.9 million in Q2 2021 per XFOR's latest filing, from $1.9 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $64.7 million in Q3 2018 and bottomed at $1.9 million in Q1 2021.
• Historically, Preferred Stock Liabilities has averaged $45.0 million across 3 years, with a median of $60.4 million in 2018.
• The widest YoY moves for Preferred Stock Liabilities: up 6.19% in 2018, down 6.19% in 2018.
• Over 3 years, Preferred Stock Liabilities stood at $60.9 million in 2017, then increased by 6.19% to $64.7 million in 2018, then sank by 97.1% to $1.9 million in 2021.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $1.9 million, $1.9 million, and $64.7 million for Q2 2021, Q1 2021, and Q4 2018 respectively.